Calcitonin controls bone formation by inhibiting the release of sphingosine 1-phosphate from osteoclasts
Open accessThe DOI matches its Crossref record; 65 of the 65 references it cites were found in a registry or an index.
Abstract
The hormone calcitonin (CT) is primarily known for its pharmacologic action as an inhibitor of bone resorption, yet CT-deficient mice display increased bone formation. These findings raised the question about the underlying cellular and molecular mechanism of CT action. Here we show that either ubiquitous or osteoclast-specific inactivation of the murine CT receptor (CTR) causes increased bone formation. CT negatively regulates the osteoclast expression of Spns2 gene, which encodes a transporter for the signalling lipid sphingosine 1-phosphate (S1P). CTR-deficient mice show increased S1P levels, and their skeletal phenotype is normalized by deletion of the S1P receptor S1P 3 . Finally, pharmacologic treatment with the nonselective S1P receptor agonist FTY720 causes increased bone formation in wild-type, but not in S1P 3 -deficient mice. This study redefines the role of CT in skeletal biology, confirms that S1P acts as an osteoanabolic molecule in vivo and provides evidence for a pharmacologically exploitable crosstalk between osteoclasts and osteoblasts.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Calcr ϩ/Ϫ (hemizygous): high bone mass, increased bone formation.”
From The Activity of Peptides of the Calcitonin Family in Bone (2019) · cites this paper as [119]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Recently, procalcitonin has been shown to inhibit osteoclast differentiation in bone marrow cultures, and interestingly, this activity was not mediated by the calcitonin receptor (CTR) (119).”
From The Activity of Peptides of the Calcitonin Family in Bone (2019) · cites this paper as [119]
The cited source says what the claim attributes to it.
In the citing paper
“Similar to the previous models of CTR deficiency, the Calcr KO mice had high bone mass because of increased bone formation, a phenotype that was then reproduced in mice that had the gene deletion restricted to the osteoclast lineage.”
From The Activity of Peptides of the Calcitonin Family in Bone (2019) · cites this paper as [119]
The cited source says what the claim attributes to it.
In the citing paper
“The study found that the loss of CTR in osteoclasts increased the levels of sphingolipid transporter 2 (SPNS2), an exporter protein required for the secretion of sphingosine-1-phosphate (S1P), which is a potent inducer of bone formation.”
From The Activity of Peptides of the Calcitonin Family in Bone (2019) · cites this paper as [119]
The cited source says what the claim attributes to it.
In the citing paper
“Therefore, according to this study, calcitonin binding to CTR on osteoclasts inhibits the expression of SPNS2, causing a drop in S1P secretion and inhibition of osteoblast activity caused by the reduced levels of S1P (119).”
From The Activity of Peptides of the Calcitonin Family in Bone (2019) · cites this paper as [119]
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Parfitt, A. M., Drezner, M. K., Glorieux, F. H., Kanis, J. A., Malluche, H., Meunier, P. J., Ott, S. M., & Recker, R. R. (1987) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650020617 · Cited by 5,016
How many drug targets are there?
Overington, J. P., Al-Lazikani, B., & Hopkins, A. L. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2199 · Cited by 3,505
Bone Histomorphometry : Standardization of Nomenclature, Symbols, and Units
PARFITT, A. M., Drezner, M. K., Glorieux, F. H., Kanis, J. А., Malluche, H. H., Meunier, P. J., Ott, S. M., & Recker, R. R. (1987) · Journal of Bone and Mineral Research · Cited by 3,258
Osteoporosis: now and the future
Rachner, T. D., Khosla, S., & Hofbauer, L. C. (2011) · The Lancet · doi:10.1016/s0140-6736(10)62349-5 · Cited by 2,696
Self-citationConditional gene targeting in macrophages and granulocytes using LysMcre mice
Clausen, B. E., Burkhardt, C., Reith, W., Renkawitz, R., & Förster, I. (1999) · Transgenic Research · doi:10.1023/a:1008942828960 · Cited by 2,098
Schwenk, F., Baron, U., & Rajewsky, K. (1995) · Nucleic Acids Research · doi:10.1093/nar/23.24.5080 · Cited by 1,289
Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis
Brinkmann, V., Billich, A., Baumruker, T., Heining, P., Schmouder, R., Francis, G., Aradhye, S., & Burtin, P. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3248 · Cited by 1,273
Skeletal remodeling in health and disease
Zaidi, M. (2007) · Nature Medicine · doi:10.1038/nm1593 · Cited by 1,069
Mechanism of Action of Oral Fingolimod (FTY720) in Multiple Sclerosis
Chun, J., & Hartung, H.-P. (2010) · Clinical Neuropharmacology · doi:10.1097/wnf.0b013e3181cbf825 · Cited by 796
Self-citationBidirectional ephrinB2-EphB4 signaling controls bone homeostasis
Zhao, C., Irie, N., Takada, Y., Shimoda, K., Miyamoto, T., Nishiwaki, T., Suda, T., & Matsuo, K. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.05.012 · Cited by 777
Cited by
Items 101–200 of 211
Baranowsky, A., Appelt, J., Tseneva, K., Jiang, S., Jahn, D., Tsitsilonis, S., Frosch, K., & Keller, J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22010449 · Cited by 13
“Since mesenchymal stem cells, including cells of the osteoblast lineage, are not only present in calvaria and bone marrow-derived osteoblast cultures, but also in bone marrow-derived osteoclast cultures [22], this observation provides a plausible explanation for the inhibitory effect of TXA on osteoclastogenesis.”
BackgroundSelf-citationAli, A., Flatt, P. R., & Irwin, N. (2024) · Clinical Medicine Insights Endocrinology and Diabetes · doi:10.1177/11795514241238059 · Cited by 13
“137 CT is known to inhibit the resorptive activity of osteoclast cells and essentially oppose the action of PTH. 138 In OVX rats, CT was demonstrated to promote bone formation by upregulating the expression of Wnt10b in osteo-clasts, 139 whilst CT receptor KO mice exhibit augmented bone formation.”
BackgroundNagata, Y., Miyagawa, K., Ohata, Y., Petrusca, D. N., Pagnotti, G. M., Mohammad, K. S., Guise, T. A., Windle, J. J., Roodman, G. D., & Kurihara, N. (2020) · Journal of Cellular Biochemistry · doi:10.1002/jcb.29861 · Cited by 13
“A recent study by Keller et al.11 supports our results that S1P from OCLs can regulate bone formation.”
BackgroundResultFingolimod suppresses bone resorption in female patients with multiple sclerosis
Miyazaki, Y., Niino, M., Kanazawa, I., Suzuki, M., Mizuno, M., Hisahara, S., Fukazawa, T., Takahashi, E., Amino, I., 越智龍太郎, et al. (2016) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2016.06.007 · Cited by 12
Nguyen, V.-T., Ko, S., Heo, S., Kang, D.-H., Oh, C., Kim, K., Jeon, Y., Kim, Y., Park, W. S., Choi, I., et al. (2018) · Process Biochemistry · doi:10.1016/j.procbio.2018.01.025 · Cited by 11
Osteogenesis Hormonal Regulation: Review
Мироманов, А. М., & Аркадьевич, Г. К. (2021) · Traumatology and Orthopedics of Russia · doi:10.21823/2311-2905-1609 · Cited by 14
Osteoblast-specific expression of Panx3 is dispensable for postnatal bone remodeling
Yorgan, T. A., Peters, S., Amling, M., & Schinke, T. (2019) · Bone · doi:10.1016/j.bone.2019.06.008 · Cited by 12
Self-citationWille, A., Weske, S., Lipinski, K. V. W., Wollnitzke, P., Schröder, N. H., Thomas, N., Nowak, M. K., Deister-Jonas, J., Behr, B., Keul, P., et al. (2024) · Journal of Bone and Mineral Research · doi:10.1093/jbmr/zjae006 · Cited by 12
“9 Additionally, S1PR3 signaling has been associated with calcification and matrix secretion in OBs, 16 as confirmed by enhanced age-related osteoporosis in S1PR3 knockout mice.”
InfluentialSelf-citationOnset of calciotropic receptors during the initiation of mandibular/alveolar bone formation
Bobek, J., Oralová, V., Lesot, H., Kratochvílová, A., Doubek, J., & Matalová, E. (2019) · Annals of Anatomy - Anatomischer Anzeiger · doi:10.1016/j.aanat.2019.151427 · Cited by 11
Sphingosine 1-phosphate and osteoporosis: pathophysiology and therapeutic aspects—a narrative review
Tian, J., Ma, S., Xie, W., Zhang, Y., Tao, L., Li, Y., & Xiao, W. (2021) · Annals of Palliative Medicine · doi:10.21037/apm-20-1255 · Cited by 13
“Bone formation is also increased by blocking the murine CT receptor (CTR) (55,56).”
BackgroundMcMullan, P., Maye, P. F., Yang, Q., Rowe, D. W., & Germain‐Lee, E. L. (2021) · JBMR Plus · doi:10.1002/jbm4.10570 · Cited by 10
“(52,68) Additional studies of the lineage-specific deletion of Calcr revealed this anabolic phenotype in vivo was primarily driven by impaired calcitonin-receptor activity specifically within the osteoclast lineage (LysM-CRE) due to elevated sphingosine-1-phosphate (S1P) release.(52) Lineage-specific loss of Calcr wit…”
BackgroundResultInfluentialDecreased Trabecular Bone Mass in Col22a1-Deficient Mice
Zhao, W., Wiedemann, P., Wölfel, E. M., Neven, M., Peters, S., Imhof, T., Koch, M., Busse, B., Amling, M., Schinke, T., et al. (2021) · Cells · doi:10.3390/cells10113020 · Cited by 10
“For bone histology, the fixed lumbar vertebral bodies L1 to L4 were dehydrated in ascending alcohol concentrations and then embedded in methylmetacrylate as described previously [23].”
MethodSelf-citationThe Ying and Yang of Sphingosine-1-Phosphate Signalling within the Bone
Frost, K., Naylor, A. J., & McGettrick, H. M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24086935 · Cited by 13
“, serum osteocalcin(OcN)/bone morphogenic protein (BMP) and collagen degradation products (carboxy-terminal collagen crosslinks: CTX) remained unaffected [29].”
BackgroundInfluentialMice Lacking the Calcitonin Receptor Do Not Display Improved Bone Healing
Appelt, J., Tsitsilonis, S., Otto, E., Jahn, D., Köhli, P., Baranowsky, A., Jiang, S., Fuchs, M., Bucher, C. H., Duda, G. N., et al. (2021) · Cells · doi:10.3390/cells10092304 · Cited by 12
“Assessment of Bone Regeneration in CTR-Deficient Mice In order to study a functional role of CT/CTR signaling in bone repair, we next assessed bone regeneration in mice lacking CTR (Calcr-/-) globally [7].”
BackgroundMethodSelf-citationA Novel Peptide, CK2.3, Improved Bone Formation in Ovariectomized Sprague Dawley Rats
Sequeira, L., Nguyen, J., Wang, L., & Nohe, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21144874 · Cited by 9
Wong, D. Y., Broberg, D. N., Doad, J. S., Umoh, J. U., Bellyou, M., Norley, C. J. D., Holdsworth, D. W., Montero‐Odasso, M., Beauchet, O., Annweiler, C., et al. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-201137 · Cited by 9
“One plausible explanation for our findings combines the effects of vitamin D on calcium homeostasis [60, 61] along with the idea that NMDAR inhibition causes decreased bone resorption [57] (Supplementary Figure 1).”
Pandya, A., Vora, L. K., Moreno‐Castellanos, N., Sabri, A. H. B., Naser, Y. A., Baviskar, S. M., Anjani, Q. K., Jahan, S. A., Thakur, R. R. S., McCarthy, H. O., et al. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.114146 · Cited by 8
Calcitonin receptor expression in medullary thyroid carcinoma
Cappagli, V., Potes, C. S., Ferreira, L. B., Tavares, C., Eloy, C., Elisei, R., Sobrinho-Simões, M. A., Wookey, P. J., & Soares, P. (2017) · PeerJ · doi:10.7717/peerj.3778 · Cited by 9
“It has been shown the osteoanabolic action of CT (Keller et al., 2014).”
BackgroundPeltier, L., Bendavid, C., Cavey, T., Island, M., Doyard, M., Leroyer, P., Allain, C., de Tayrac, M., Ropert, M., Loréal, O., et al. (2018) · Osteoporosis International · doi:10.1007/s00198-018-4531-8 · Cited by 10
Jourdain, M., Sergheraert, J., Braux, J., Guillaume, C., Gangloff, S. C., Hubert, D., Velard, F., & Jacquot, J. P. (2020) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2020.166010 · Cited by 10
Ostrovskaya, A. V., Findlay, D. M., Sexton, P. M., & Furness, S. G. B. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-809324-5.03223-5 · Cited by 8
Effects of Drugs on Bone Quality
Imbert, L., & Boskey, A. L. (2016) · Clinical Reviews in Bone and Mineral Metabolism · doi:10.1007/s12018-016-9220-6 · Cited by 9
“in bone mass was attributed to inhibited release of sphingosine-1-phosphate, a lipid signaling agent from osteoclasts [37].”
BackgroundCalcitonin Response to Naturally Occurring Ionized Hypercalcemia in Cats with Chronic Kidney Disease
van den Broek, D. H. N., Geddes, R. F., Williams, T., Chang, Y., Elliott, J., & Jepson, R. E. (2018) · Journal of Veterinary Internal Medicine · doi:10.1111/jvim.15051 · Cited by 11
“It presumably inhibits osteoclast-mediated stimulation of osteoblast activity, and thereby indirectly reduces bone formation.(19,51) In addition, high or potent doses of calcitonin were shown to directly inhibit osteoclastic bone resorption.”
BackgroundWalker, J. M., Yao, G., Siu, E., Zhu, M., Sun, B., Simpson, C. A., & Insogna, K. L. (2021) · Endocrinology · doi:10.1210/endocr/bqab042 · Cited by 8
Donat, A., Jiang, S., Xie, W., Knapstein, P. R., Albertsen, L.-C., Kokot, J. L., Sevecke, J., Augustin, R., Jahn, D., Yorgan, T. A., et al. (2023) · iScience · doi:10.1016/j.isci.2023.107761 · Cited by 9
Self-citationWagner, J. M., Wille, A., Fueth, M., Weske, S., Lotzien, S., Reinkemeier, F., Wallner, C., Sogorski, A., Dittfeld, S., Becerikli, M., et al. (2023) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.17952 · Cited by 7
“25 In our present study, we have observed that the benefit of S1P lyase inhibition on bone regeneration in posttraumatic osteomyelitis was abolished in S1PR3 deficient mice.”
BackgroundSelf-citationAdenoviral delivery of adiponectin ameliorates osteogenesis around implants in ovariectomized rats
Yin, G., Liu, H., Li, J., Liu, Y., Liu, X., & Luo, E. (2019) · The Journal of Gene Medicine · doi:10.1002/jgm.3069 · Cited by 7
Shin, B., Hrdlicka, H. C., Delany, A. M., & Lee, S. (2021) · Endocrinology · doi:10.1210/endocr/bqab135 · Cited by 8
Jiang, S., Xie, W., Knapstein, P. R., Donat, A., Albertsen, L.-C., Sevecke, J., Erdmann, C., Appelt, J., Fuchs, M., Hildebrandt, A., et al. (2024) · Communications Biology · doi:10.1038/s42003-024-05889-0 · Cited by 7
Self-citationAdvances in Molecularly Imprinted Polymers for Bone Biomarker Detection and Therapeutic Applications
Yang, R., Ma, X., Xuan, M., Ma, Y., Ding, J.-X., Chau, D. Y. S., Knowles, J. C., Peng, F., & Poma, A. (2025) · ChemistryOpen · doi:10.1002/open.202500127 · Cited by 7
Parathyroid Hormone, Parathyroid Hormone–Related Protein, and Calcitonin
Wysolmerski, J. J. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-809965-0.00046-x · Cited by 6
Heckt, T., Brylka, L., Neven, M., Amling, M., & Schinke, T. (2019) · PLoS ONE · doi:10.1371/journal.pone.0219734 · Cited by 6
Self-citationRolvien, T., Avci, O., Kroge, S. V., Koehne, T., Selbert, S., Sonntag, S., Shmerling, D., Kornak, U., Oheim, R., Amling, M., et al. (2020) · Bone Reports · doi:10.1016/j.bonr.2020.100281 · Cited by 6
Self-citationZhu, M., Sun, B., Nevius, E., Kaplan, J. M., Pereira, J. P., & Insogna, K. L. (2021) · PLoS ONE · doi:10.1371/journal.pone.0247199 · Cited by 6
“Sphingosine-1-phosphate is a known anabolic clastokine [29, 30].”
Sopova, J. V., Krasnova, O. A., Kriukova, J. D., Mukhamedshina, Y. O., Zakirova, E. Y., Rizvanov, A. A., Lesnyak, O. M., & Neganova, I. E. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1684658 · Cited by 6
“The rs1801197 ( CALCR ) polymorphism has also been linked to an elevated risk of osteoporosis in several studies (184), potentially impairing the receptor ’ s physiological function as a key inhibitor of osteoclast-mediated bone resorption (185).”
Manglani, K., Vijayan, V., Pathak, C., Khandelwal, M., Singh, P. P., Chellappa, S., Yadav, V. K., Surolia, A., & Gupta, S. (2019) · Bone · doi:10.1016/j.bone.2019.02.019 · Cited by 5
Key role for S1P in bone remodelling
Holmes, D. I. R. (2014) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2014.190 · Cited by 5
Using mouse genetics to understand human skeletal disease
Youlten, S. E., & Baldock, P. A. J. (2019) · Bone · doi:10.1016/j.bone.2019.02.015 · Cited by 5
Multiple Endocrine Neoplasia Syndromes
Newey, P. J., & Thakker, R. V. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-804182-6.00038-1 · Cited by 5
Ahmadipour, S., Varshosaz, J., Hashemibeni, B., Manshaei, M., & Safaeian, L. (2022) · Drug Development and Industrial Pharmacy · doi:10.1080/03639045.2022.2087080 · Cited by 4
“Therefore, S1P levels are increased in CTR-deficient mice, resulting in the normalization of their skeletal phenotype [15].”
BackgroundYao, G., Zhu, M., Walker, J. M., & Insogna, K. L. (2020) · Calcified Tissue International · doi:10.1007/s00223-020-00685-4 · Cited by 4
“In vivo and in vitro evidence indicate that Sphingosine1-Phosphate (S1P) is a clastokine that can augment osteoblast function [3, 4].”
BackgroundInfluentialOsterberg, A., Engelmann, R., & Müller‐Hilke, B. (2017) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-017-0859-y · Cited by 4
Feng, S., Wang, H., Yan, Y., Su, X., Ao, J., & Chen, W. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.756957 · Cited by 5
“It may play a protective role regarding BMD by inhibiting the bone resorption function of osteoclasts (Keller et al., 2014).”
BackgroundWu, K., Chen, Y., Lin, S., & Chang, C.-H. (2021) · Journal of Biomaterials Applications · doi:10.1177/0885328221989984 · Cited by 5
“In addition, calcitonin participates in the cross-talk between osteoclasts and osteoblasts, thereby regulating bone formation.(40) In addition to osteoclasts, osteocytes also express calcitonin receptor.”
BackgroundCalcitonin and procalcitonin: Revisiting the overlooked role of C cells
Fröhlich, E., & Wahl, R. (2025) · Metabolism · doi:10.1016/j.metabol.2025.156434 · Cited by 4
Hao, D., Han, H., Li, D., Sun, Y., Wang, Y., Yan, H., Li, G., Liu, H., Li, B., Li, F., et al. (2026) · Poultry Science · doi:10.1016/j.psj.2026.106649 · Cited by 3
“The elevated Ca content may stimulate thyroid C cells to secrete CT (Deftos et al., 1973), which inhibits osteoclast-mediated bone resorption (Keller et al., 2014; Lucht, 1973), facilitating Ca redeposition in medullary bone to establish a Ca reserve for eggshell calcification (Teng et al., 2020)…”
Inactivation of spermine synthase in mice causes osteopenia due to reduced osteoblast activity
Yorgan, T. A., Zhu, Y., Wiedemann, P., Schöneck, K., Pohl, S., Schweizer, M., Amling, M., Barvencik, F., Oheim, R., & Schinke, T. (2024) · Journal of Bone and Mineral Research · doi:10.1093/jbmr/zjae156 · Cited by 3
Self-citationCxcl9-deficiency attenuates the progression of post-traumatic osteoarthritis in mice
Donat, A., Xie, W., Jiang, S., Brylka, L., Schinke, T., Rolvien, T., Frosch, K., Baranowsky, A., & Keller, J. (2025) · Inflammation Research · doi:10.1007/s00011-025-02013-8 · Cited by 3
Self-citationSphingosine kinase activity and sphingosine‐1‐phosphate in the inflamed human periodontium
Hamdan, N., Bhagirath, A. Y., & Júnior, E. L. B. (2021) · Oral Diseases · doi:10.1111/odi.13995 · Cited by 3
Inactivation of the gene encoding procalcitonin prevents antibody-mediated arthritis
Maleitzke, T., Dietrich, T., Hildebrandt, A., Weber, J., Appelt, J., Jahn, D., Otto, E., Zocholl, D., Jiang, S., Baranowsky, A., et al. (2023) · Inflammation Research · doi:10.1007/s00011-023-01719-x · Cited by 4
“Calca−/− mice display an agedependent, elevated bone turnover which results in increased cortical and calvarial porosity in aged mice [5, 17].”
BackgroundMethodSelf-citationRepurposing the multiple sclerosis drug Siponimod for osteoporosis treatment
Hu, S., Hu, Y., Tan, Z., Zhou, C., Zhang, C., Yin, S., Chen, X., Chen, K., Wang, L., & Chen, L. (2024) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2024.176630 · Cited by 3
Biophysics and the nonlinear dynamics instigated by a special hormone
Javed, S., Sohail, A., Asif, A., & Nutini, A. (2019) · Progress in Biophysics and Molecular Biology · doi:10.1016/j.pbiomolbio.2019.05.005 · Cited by 3
No obvious phenotypic abnormalities in mice lacking the Pate4 gene
Heckt, T., Keller, J., Reusch, R., Hartmann, K., Krasemann, S., Hermans‐Borgmeyer, I., Amling, M., & Schinke, T. (2015) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2015.12.104 · Cited by 3
Self-citationEffect of calcitonin on cultured schwann cells
Yan, J., Zhang, L., Agresti, M., Shen, F., Matloub, H. S., Yan, Y., Li, J., Gu, Y., LoGiudice, J. A., & Havlik, R. J. (2016) · Muscle & Nerve · doi:10.1002/mus.25519 · Cited by 3
Coester, B., Lutz, T. A., & Foll, C. L. (2022) · Metabolites · doi:10.3390/metabo12010051 · Cited by 3
“Jean-Pierre David and Dr Thorsten Schinke, University Medical Center Hamburg [37,38].”
BackgroundMethodNaot, D., Musson, D. S., & Cornish, J. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-814841-9.00033-6 · Cited by 4
Evidence for altered osteoclastogenesis in splenocyte cultures from VDR knockout mice
Reinke, D. C., Starczak, Y., Kogawa, M., Barratt, K. R., Morris, H. A., Anderson, P., & Atkins, G. J. (2017) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2017.07.033 · Cited by 3
Zhang, L., Kaji, T., Nakamura, A., Maesawa, N., Iwamori, K., Xu, J., Liu, Y., Uezumi, A., Kamimura, D., Murakami, M., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-65684-1 · Cited by 3
“In the wheel-running mice, IL-6 levels were remarkably elevated compared to both non-exercised and treadmill-running mice.”
Qiu, H., Liu, S., Jiang, Y., Lai, Y., Lin, Q., & Huang, A. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1821292 · Cited by 3
“Cathepsin K inhibits SPHK1, while calcitonin suppresses SPNS2 expression (132, 133).”
Neuro-osteo crosstalk: The sympathetic nervous system as a key driver of SCI-induced osteoporosis
Bryan, J. A., Jackson, W., Lemmens, N., & Hook, M. A. (2026) · Experimental Neurology · doi:10.1016/j.expneurol.2026.115824 · Cited by 2
Rauner, M., & Hofbauer, L. C. (2016) · Springer eBooks · doi:10.1007/978-3-319-34238-2_1 · Cited by 4
Self-citationatabi, H. S. H. A., Tobji, S., & Haouas, Z. (2023) · Journal of Craniofacial Surgery · doi:10.1097/scs.0000000000009575 · Cited by 2
“18,19 Calcitonin may also help increase the amount of alveolar bone in addition to these bene fi ts. Sutural separation is increased by limiting the activity of osteoclasts and stimulating osteoblasts, which reduces bone mineral resorption and increases bone growth and density.”
BackgroundLevasseur, R. (2019) · EMC - Aparato Locomotor · doi:10.1016/s1286-935x(19)42130-8 · Cited by 6
Abordagem farmacológica em lesão central de células gigantes: Relato de caso
Loureiro, A. M. L. C., da Silva, C. L., Nunes, L. S. D. O., Theotonio, P. E. S., Santana, S. F., Franco, Á. V. D. M., & Nogueira, P. T. B. D. C. (2019) · Revista Eletrônica Acervo Saúde · doi:10.25248/reas.e2111.2019 · Cited by 2
The high bone mass phenotype of Lrp5-mutant mice is not affected by megakaryocyte depletion
Yorgan, T. A., David, J., Amling, M., & Schinke, T. (2018) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2018.02.127 · Cited by 2
Self-citationThe Species Effect: Differential Sphingosine-1-Phosphate Responses in the Bone in Human Versus Mouse
Frost, K., Lewis, J. W., Jones, S. W., Edwards, J., Naylor, A. J., & McGettrick, H. M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25105118 · Cited by 3
“…several studies have investigated the functional consequence of S1P on osteoblastogenesis, inconsistencies in the reported expression pattern of the five S1P receptors on osteoblasts and their precursors [4,5], and how these change upon maturation [6,7], adds to the complexity within the field.”
BackgroundCellular actions of parathyroid hormone on bone
Ambrogini, E., & Jilka, R. L. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-814841-9.00032-4 · Cited by 3
Bioactive lipids and cancer metastasis to bone
Saier, L., Niazi, H., Brizuela, L., Levkau, B., & Peyruchaud, O. (2021) · Journal of Cancer Metastasis and Treatment · doi:10.20517/2394-4722.2021.87 · Cited by 3
Self-citationBone Regeneration with Stem Cells from Dental Pulp in a Rat Experimental ModelPreprint
Hamad-Alrashid, H., Muntión, S., Sanchez-Guijo, F. M., Borrajo-Sánchez, J., Parreño-Manchado, F. C., Cenador, M. B. G., & García‐Criado, F. J. (2024) · Preprints.org · doi:10.20944/preprints202403.1012.v1 · Cited by 2
Levasseur, R. (2019) · EMC - Podología · doi:10.1016/s1762-827x(19)42712-0 · Cited by 1
Maniaki, E., Pineda, C., Hibbert, A., & Finch, N. (2024) · Frontiers in Veterinary Science · doi:10.3389/fvets.2024.1399942 · Cited by 2
“Calcitonin restores normocalcemia by predominantly inhibiting osteoclastic bone resorption (1–3), but also by decreasing renal tubular reabsorption of calcium (4).”
BackgroundAhmadpour, E., Azizi, B., Zarei, S., Azizi, H., Javadi, S., Hagh, E. J., & Ahmadpour, F. (2025) · Journal of Craniofacial Surgery · doi:10.1097/scs.0000000000010310 · Cited by 1
“9 It is a proven fact that CT plays a physiological role and regulates homeostasis or calcium, 10 and is a critical regulator for the metabolism of bone.”
Castro, N. M., Wang, J. K., Tergaonkar, V., Tan, N. S., Tanner, K. E., & Tay, C. Y. (2025) · Biofabrication · doi:10.1088/1758-5090/ae1878 · Cited by 1
“In osteo-lytic lesions, tumour-induced acidification destabil-ises the collagen–HA interface—maintained by ionic bonds between calcium ions and phosphate groups— further weakening bone integrity (Keller et al 2014).”
Study of the modulating factors combined action on reparative osteogenesis
Konovalenko, S. V., Protsenko, V. V., Tykhonov, V. H., Solonitsyn, Y. О., Hrebennikov, Y. K., Konovalenko, V. F., & Mk, T. (2025) · TRAUMA · doi:10.22141/1608-1706.4.26.2025.1028 · Cited by 1
Ren, W.-H., Wang, R., Zhang, G.-J., Zhen, C., Liu, J.-Y., Wei, S.-Q., Wang, L.-J., Yang, Z.-Q., & Shang, P. (2026) · Acta Astronautica · doi:10.1016/j.actaastro.2026.02.044 · Cited by 1
Vitamin D and Sphingolipids: Role in Bone and Neural System
Frati, A., Garcia‐Gil, M., Pierucci, F., & Meacci, E. (2017) · InTech eBooks · doi:10.5772/66648
“[115] report that the release of S1P by osteoclasts is regulated by calcitonin.”
BackgroundWolde-Semait, H. T., & Komlos, D. (2020) · Springer eBooks · doi:10.1007/978-3-030-33861-9_1 · Cited by 2
Osteoblast biology: developmental origin and interactive nature of osteoblasts
van der Eerden, B. C. J., & van Wijnen, A. J. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-813073-5.00006-x · Cited by 3
Xu, C., Xiao, Y., Wu, Y., Bakker, A. D., & Liu, Y. (2024) · Regenerative medicine and dentistry. · doi:10.53941/rmd.2024.100005 · Cited by 2
Effect of thyroid function on periodontitis in U.S. populationPreprint
han, W., mingjun, Z., Li, N., miao, X., ka, C., abulikemu, P., & hongli, S. (2023) · Research Square · doi:10.21203/rs.3.rs-3139548/v1 · Cited by 1
Gu, Y. (2018) · Biomedical Journal of Scientific & Technical Research · doi:10.26717/bjstr.2018.06.001332
“4/7 Biomedical Journal of Scientific & Technical Research (BJSTR) TNF-alfa23 Increase (low OPG) N/A Increase RANK expression N/A An antagonist to treat osteoporosis: Denosumab IL-123 Increase (low OPG) N/A Increase RANK expression N/A An antagonist to treat rheumatoid arthritis: Ankinra Histamine24 Increase (high RANK…”
BackgroundInfluentialShang, N., & Wu, J. (2019) · Royal Society of Chemistry eBooks · doi:10.1039/9781788013833-00135 · Cited by 2
Evaluation of Smart Polymers for Controlled Release Delivery Systems
Lipp, L. (2019) · NDSU Repository (North Dakota State University)
Quantification of Sphingosine-1-Phosphate (S1P) in Patients with Periodontitis Stage II Grade B
García-Parra, M. I., Jiménez‐Coello, M., Carrillo-Ávila, B. A., Sauri-Esquivel, E. A., Martínez-Aguilar, V. M., & Chávez-Cortéz, E. G. (2021) · Odovtos - International Journal of Dental Sciences · doi:10.15517/ijds.2022.48877 · Cited by 1
“Once differentiated, osteoclasts can also produce S1P, creating a bi-directional feed circuit for osteoclastogenesis (14,33,34).”
BackgroundCellular and Molecular Biology in Bone Remodeling
DeNapoli, R. C., Buettmann, E. G., & Donahue, H. J. (2021) · Springer eBooks · doi:10.1007/978-981-16-5613-2_1 · Cited by 1
Lee, S., & Pioszak, A. A. (2017) · Springer eBooks · doi:10.1007/978-3-319-67199-4_101586
Lee, S.-M., & Pioszak, A. A. (2016) · Springer eBooks · doi:10.1007/978-1-4614-6438-9_101586-1
Calcitonin acts on osteoclasts to regulate bone formation
(2015) · IBMS BoneKEy · doi:10.1038/bonekey.2015.25
Genesis of Osteoclasts on Calcium Phosphate Ceramics and its Role in Material-Induced Bone FormationPreprint
Nie, Z., Hu, Z., Guo, X., Xiao, Y., Liu, X., de Bruijn, J. D., Bao, C., & Yuan, H. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4163651
MODERN SOCIETY & SCIENCE PROGNOSIS & ACHIEVEMENT
IRETC, & Isazade, N. (2022) · IRETC eBooks · doi:10.36962/msspa01012022
Hildebrandt, A., Dietrich, T., Weber, J., Günderoth, M. M., Zhou, S., Fleckenstein, F. N., Jiang, S., Winkler, T., Duda, G. N., Tsitsilonis, S., et al. (2023) · Figshare · doi:10.6084/m9.figshare.24844664
Self-citationYao, G., Zhu, M., & Insogna, K. L. (2026) · Bone Reports · doi:10.1016/j.bonr.2025.101896
“…it has been reported that sCSF1 stimulates transcription of sphingosine kinase 1 (SPHK1) (Yao et al., 2016; Yao et al., 2020), which is the rate-limiting enzyme for the production sphingosine-1-phosphate (S1P), a known anabolic clastokine (Yao et al., 2017; Xu et al., 2023; Keller et al., 2014).”
Jiang, S., Xie, W., Ballhause, T. M., Sevecke, J., Augustin, R., Rolvien, T., Maleitzke, T., Baranowsky, A., & Keller, J. (2026) · Bone and Joint Research · doi:10.1302/2046-3758.152.bjr-2025-0025.r1 · Cited by 1
“Contrary to the primarily antiresorptive efect of fsh CT, we previously showed that endogenous CT suppresses bone formation by regulating osteoclast-osteo blast crosstalk, - 11 establishing a clear distinction between the pharmacological and endogenous functions of CT in mammalian bone remodelling.”
InfluentialSelf-citationMultiple endocrine neoplasia syndromes
Newey, P. J., & Thakker, R. V. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-13683-2.00033-5
Conigrave, A. D., & Ward, D. T. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-13683-2.00045-1 · Cited by 1
di Filippo, L., Franzese, V., Incampo, G., Formenti, A. M., Albanese, L., Doga, M., Onorati, D., Maggiore, R., Rosati, R., Perticone, F., et al. (2026) · Bone · doi:10.1016/j.bone.2026.117872
Metadata
- Authors
- Keller, J., Catala-Lehnen, P., Huebner, A. K., Jeschke, A., Heckt, T., Lueth, A., Krause, M., Koehne, T., Albers, J., Schulze, J., Schilling, S., Haberland, M., Denninger, H., Neven, M., Hermans-Borgmeyer, I., Streichert, T., Breer, S., Barvencik, F., Levkau, B., Rathkolb, B., Wolf, E., Calzada-Wack, J., Neff, F., Gailus-Durner, V., Fuchs, H., de Angelis, M. H., Klutmann, S., Tsourdi, E., Hofbauer, L. C., Kleuser, B., Chun, J., Schinke, T., & Amling, M.
- Affiliations
- University Medical Center Hamburg-Eppendorf (DE)
- University of Potsdam (DE)
- Essen University Hospital (DE)
- Helmholtz Munich (DE)
- Ludwig-Maximilians-Universität München (DE)
- Scripps Research Institute (US)
- Corresponding author
- Amling, Michael
- ORCID
- Venue
- Nature Communications
- Published
- 2014-10-21
- Volume
- 5
- Issue
- 1
- Pages
- 5215-5215
- ISSN
- 2041-1723 (ISSN-L)
- PMC
- PMC4205484
- OpenAlex
- W1980751002
- Semantic Scholar
- e2f2d551f2624d9e90a89e2ee5d3017852508fd9
- Cited by
- 211
- References
- 64
- Citations by year
- 2026: 16 · 2025: 9 · 2024: 16 · 2023: 13 · 2022: 10 · 2021: 27 · 2020: 24 · 2019: 29 · 2018: 16 · 2017: 22 · 2016: 12 · 2015: 15 · 2014: 2
- FWCI
- 6.97
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Nature Communications (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Open access LMU (Ludwid Maxmilian's Universitat Munchen) (submittedVersion)
- publish.UP (University of Potsdam) (submittedVersion)
- mediaTUM (Technical University of Munich) (submittedVersion, other-oa)
- Site cant be reached (submittedVersion)
- OpenAgrar (submittedVersion)
- Funders
- INFRAFRONTIER (01KX1012)
- Deutsche Forschungsgemeinschaft (AM103/15-1, DA019674, 01KX1012)
- Bundesministerium für Bildung und Forschung (01GS0850, 01KX1012, 01GS0851)
- National Institutes of Health (5r01da019674-05, DA019674)
- National Institute on Drug Abuse (DA019674, R01-DA019674)
- National Institute on Deafness and Other Communication Disorders (DC009505, R21DC009505)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Sphingolipid Metabolism and Signaling
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Keywords
- calcitonin, calcitonin receptor, bone formation, osteoclasts, sphingosine-1-phosphate, S1P3 receptor, SPNS2, fingolimod, bone resorption, skeletal phenotype
- MeSH terms
- Alleles, Animals, Bone and Bones, Calcitonin, Crosses, Genetic, Female, Lysophospholipids, Mice, Inbred C57BL, Mice, Transgenic, Osteoblasts, Osteoclasts, Osteogenesis, Osteoporosis, Phenotype, Sphingosine, Signal Transduction, Porosity, Collagenases, Receptors, Calcitonin, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.